IDEXX Laboratories, Inc. (IDXX) Chairman Sells $3,905,440.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 22,000 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $177.52, for a total transaction of $3,905,440.00. Following the transaction, the chairman now owns 1,077,112 shares of the company’s stock, valued at approximately $191,208,922.24. The transaction was disclosed in a document filed with the SEC, which is available at this link.

IDEXX Laboratories, Inc. (IDXX) traded up $3.67 during trading hours on Friday, reaching $172.95. The company had a trading volume of 726,045 shares, compared to its average volume of 606,923. IDEXX Laboratories, Inc. has a 12-month low of $140.63 and a 12-month high of $198.73. The firm has a market capitalization of $15,422.88, a P/E ratio of 58.83, a P/E/G ratio of 2.17 and a beta of 0.58. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The firm’s revenue was up 14.2% on a year-over-year basis. equities analysts predict that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

A number of analysts have commented on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Friday. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price target for the company in a research report on Monday. Bank of America increased their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies increased their price objective on IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $194.00.

A number of large investors have recently added to or reduced their stakes in the stock. Advisors Capital Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $262,000. Koch Industries Inc. grew its stake in shares of IDEXX Laboratories by 44,533.1% in the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of IDEXX Laboratories by 7.8% in the third quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock worth $52,706,000 after acquiring an additional 24,510 shares during the last quarter. Cabot Wealth Management Inc. acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $1,359,000. Finally, Macquarie Group Ltd. lifted its position in IDEXX Laboratories by 7.0% in the third quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock worth $5,909,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 86.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/09/idexx-laboratories-inc-idxx-chairman-sells-3905440-00-in-stock.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply